GSK reportedly being investigated for Mideast behavior

Share this article:

The Wall Street Journal reported Sunday that GlaxoSmithKline is allegedly being investigated over unethical behavior in the Middle East. The WSJ says it has seen emails with allegations that track closely with previous allegations of improper behavior in China that plagued the company over the last year.

An inside source tells the paper that he believes GSK “practices in Iraq violate the FCPA and the UK Bribery Act.” FCPA refers to the US Foreign Corrupt Practices Act. Allegations include paying government-supported healthcare providers to double as sales representatives and providing “high fees...in exchange for promoting and prescribing its drugs.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.